Literature DB >> 21772748

Bromocriptine or cabergoline induced pituitary apoplexy: Rare but life-threatening catastrophe.

Pratibha Singh1, Manish Singh, Goutham Cugati, Ajai Kumar Singh.   

Abstract

Entities:  

Year:  2011        PMID: 21772748      PMCID: PMC3136076          DOI: 10.4103/0974-1208.82367

Source DB:  PubMed          Journal:  J Hum Reprod Sci        ISSN: 1998-4766


× No keyword cloud information.
Sir, Prolactin secreting pituitary tumor is one of the common causes of infertility in males and females.[1] Prolactin level is also high in non-prolactin secreting pituitary adenoma (e.g., growth hormone secreting) due to stalk effect.[2] Most of the prolactinomas can be managed medically with bromocriptine or cabergoline which are largely used as primary treatment for prolactinomas, as they help to normalize serum prolactin levels and induce reduction in the tumor size, promoting restoration of gonadal function, cessation of galactorrhea and improvement in visual defects in the majority of patients.[12] Bromocriptine or cabergoline induced pituitary apoplexy is a life-threatening complication which is rare but well known.[2-5] This condition is characterized by sudden onset of headache, visual loss or deterioration, meningismus, altered mental status, and rarely, even death.[12] This pathology is caused by hemorrhagic necrosis of tumor or pituitary gland infarction, in which pituitary function is compromised, necessitating rapid administration of corticosteroids and endocrine evaluation.[1] Rapid surgical decompression is required if there is sudden constriction of visual fields, and/or rapid deterioration of acuity, or neurological deterioration due to hydrocephalus.[12] These reports point toward the possibility of bromocriptine or cabergoline induced pituitary apoplexy, which should be kept in mind when a patient is neurologically deteriorating after starting these drugs. Careful follow-up is required when treatment with bromocriptine or cabergoline is attempted for prolactinoma in reproductive medicine clinic for infertility management in male and female patients.
  4 in total

1.  Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.

Authors:  Mirta Knoepfelmacher; Miriam C Gomes; Maria E Melo; Berenice B Mendonca
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

2.  Pituitary apoplexy in an adolescent with prolactin-secreting adenoma.

Authors:  G Pinto; M Zerah; C Trivin; R Brauner
Journal:  Horm Res       Date:  1998

3.  Pituitary apoplexy in acromegaly during bromocriptine therapy.

Authors:  T Yamaji; M Ishibashi; K Kosaka; T Fukushima; T Hori; S Manaka; K Sano
Journal:  Acta Endocrinol (Copenh)       Date:  1981-10

4.  Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma.

Authors:  K Shirataki; K Chihara; Y Shibata; N Tamaki; S Matsumoto; T Fujita
Journal:  Neurosurgery       Date:  1988-09       Impact factor: 4.654

  4 in total
  1 in total

1.  Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline.

Authors:  Hesam Ghadirian; Mohamad Shirani; Shahab Ghazi-Mirsaeed; Saleh Mohebi; Maysam Alimohamadi
Journal:  Asian J Neurosurg       Date:  2018 Jan-Mar
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.